John-paul P. Westwood

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications

Recurrent thrombocytopenia in immune thrombotic thrombocytopenic purpura during the caplacizumab era.

Recurrent thrombocytopenia in immune thrombotic thrombocytopenic purpura during the caplacizumab era.

Journal: British journal of haematology
Published: March 25, 2026

Delayed ADAMTS13 normalisation in caplacizumab/PEX treated patients associated with anti-ADAMTS13 IgG antibody boosting.

Delayed ADAMTS13 normalisation in caplacizumab/PEX treated patients associated with anti-ADAMTS13 IgG antibody boosting.

Journal: Blood advances
Published: January 09, 2026

Delayed ADAMTS13 normalization in caplacizumab/PEX-treated patients associated with anti-ADAMTS13 IgG antibody boosting.

Delayed ADAMTS13 normalization in caplacizumab/PEX-treated patients associated with anti-ADAMTS13 IgG antibody boosting.

Journal: Blood advances
Published: January 09, 2026

Long-term follow-up outcomes in congenital thrombotic thrombocytopenic purpura.

Long-term follow-up outcomes in congenital thrombotic thrombocytopenic purpura.

Journal: Blood
Published: May 05, 2025

Acquired Glanzmann's thrombasthenia with IgG and IgA against activated αIIb β3.

Acquired Glanzmann's thrombasthenia with IgG and IgA against activated αIIb β3.

Journal: British journal of haematology
Published: May 12, 2023

A British Society for Haematology Guideline: Diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies.

A British Society for Haematology Guideline: Diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies.

Journal: British journal of haematology
Published: April 25, 2023

Delayed normalization of ADAMTS13 activity in acute thrombotic thrombocytopenic purpura in the caplacizumab era.

Delayed normalization of ADAMTS13 activity in acute thrombotic thrombocytopenic purpura in the caplacizumab era.

Journal: Blood
Published: October 27, 2022

Long-term risk of relapse in immune-mediated thrombotic thrombocytopenic purpura and the role of anti-CD20 therapy.

Long-term risk of relapse in immune-mediated thrombotic thrombocytopenic purpura and the role of anti-CD20 therapy.

Journal: Blood
Published: May 13, 2022

Pharmacological venous thromboembolism prophylaxis in elective cranial surgery: a systematic review of time of initiation, regimen and duration.

Pharmacological venous thromboembolism prophylaxis in elective cranial surgery: a systematic review of time of initiation, regimen and duration.

Journal: British journal of neurosurgery
Published: April 21, 2022

The use of obinutuzumab and ofatumumab in the treatment of immune thrombotic thrombocytopenic purpura.

The use of obinutuzumab and ofatumumab in the treatment of immune thrombotic thrombocytopenic purpura.

Journal: British journal of haematology
Published: February 10, 2022

IVIg-exposure and thromboembolic event risk: findings from the UK Biobank.

IVIg-exposure and thromboembolic event risk: findings from the UK Biobank.

Journal: Journal of neurology, neurosurgery, and psychiatry
Published: January 17, 2022

Real-world, single-center experience of SARS-CoV-2 vaccination in immune thrombocytopenia.

Real-world, single-center experience of SARS-CoV-2 vaccination in immune thrombocytopenia.

Journal: Journal of thrombosis and haemostasis : JTH
Published: October 05, 2021
Showing 1-12 of 28

Last Updated: 09/26/2026